Loading stock data…
ABSI
$4.92-0.05 (-1.11%)
Market ClosedLast close May 1
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Absci Corporation in the Healthcare sector is trading at $4.92. The stock is currently near its 52-week high of $5.23, remaining 54.2% above its 200-day moving average. Technical signals show overbought RSI of 83 and bullish MACD crossover, explaining why ABSI maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 83) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.92
Potential Upside
5%
Whystock Fair Value$5.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bow...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$579.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.01
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.80%
Volume
Today's trading volume
2.58M
Recent News
Absci Corp. (ABSI) Offering Impressive Upside to Potential Investors
Absci Corp. (NASDAQ:ABSI) is one of the 10 most shorted penny stocks to buy. As of the April 23 closing, the stock carries a strongly bullish consensus sentiment. Of the 7 analysts who provided coverage, 6 assigned Buy ratings and 1 gave a Hold call. It has a median 1-year target price of $7.64, leading […]
Absci Highlights AI Antibody Platform, Teases ABS-201 Hair-Loss Data and 2026 Milestones at Needham Conference
Absci (NASDAQ:ABSI) used a presentation at the Needham Healthcare Conference to outline how it is applying artificial intelligence to antibody discovery and development, while sharpening investor focus on its lead clinical program, ABS-201, in androgenic alopecia (AGA) and endometriosis. The discuss
Here's Why We're Watching Absci's (NASDAQ:ABSI) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Absci (ABSI) Q4 2025 Earnings Call Transcript
Joining me today are Sean McClain, Absci Corporation’s Founder and CEO; Zach Jonasson, Chief Financial Officer and Chief Business Officer; and Ronti Somerotne, Absci Corporation’s new Chief Medical Officer. Before we begin, I would like to remind you that management will make statements during the call that are forward-looking within the meaning of the federal securities laws.
Absci Corporation Q4 2025 Earnings Call Summary
Moby summary of Absci Corporation's Q4 2025 earnings call